Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Breast 3Head & Neck 2Genitourinary 2Thoracic 1Gynecologic 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
soluble LAG-3 protein, human × Breast × Clear all
NCT05747794 2024-12-17

AIPAC-003

Immutep S.A.S.

Phase 2/3 Active not recruiting
849 enrolled
Breast

Breast Neoplasms

NCT04252768 2023-03-22

AIPAC-002

Immutep S.A.S.

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00349934 2010-01-07

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Immutep S.A.S.

Phase 1 Completed
33 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡